Paritaprevir

Hepatitis C Virus NS3/4A Protease Inhibitor — ANTIINFECTIVES FOR SYSTEMIC USE

Key facts

Paritaprevir is an ofm drug in the Hepatitis C Virus NS3/4A Protease Inhibitor class catalogued in DrugCentral. It was first approved by the EMA in 2014. Its mechanism of action is classified as Breast Cancer Resistance Protein Inhibitors, HCV NS3/4A Protease Inhibitors and Organic Anion Transporting Polypeptide 1B1 Inhibitors. Recorded indications include Chronic hepatitis C.

• Approval status: ofm (first approved 2014 by the EMA).
• Drug class: Hepatitis C Virus NS3/4A Protease Inhibitor.
• Mechanism of action: Breast Cancer Resistance Protein Inhibitors; HCV NS3/4A Protease Inhibitors; Organic Anion Transporting Polypeptide 1B1 Inhibitors.
• Indications: Chronic hepatitis C.
• ATC code: J05AP52 (Antivirals for treatment of HCV infections).
• Molecular formula: C40H43N7O7S; molecular weight 765.89 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Chronic hepatitis C

Mechanism & targets

• Mechanism of action (MoA): Breast Cancer Resistance Protein Inhibitors; HCV NS3/4A Protease Inhibitors; Organic Anion Transporting Polypeptide 1B1 Inhibitors; Organic Anion Transporting Polypeptide 1B3 Inhibitors; P-Glycoprotein Inhibitors; UGT1A1 Inhibitors
• Established pharmacologic class: Hepatitis C Virus NS3/4A Protease Inhibitor

Regulatory approvals (2)

Date	Agency	Marketed as	Applicant	Orphan
2014-12-19	FDA	—	ABBVIE INC
2014-11-20	EMA	—	—

ATC classification

ATC code	Therapeutic hierarchy
J05AP52	ANTIINFECTIVES FOR SYSTEMIC USE › ANTIVIRALS FOR SYSTEMIC USE › DIRECT ACTING ANTIVIRALS › Antivirals for treatment of HCV infections
J05AP53	ANTIINFECTIVES FOR SYSTEMIC USE › ANTIVIRALS FOR SYSTEMIC USE › DIRECT ACTING ANTIVIRALS › Antivirals for treatment of HCV infections

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Drug interaction	237.8
Hyperbilirubinaemia	100.1
Hepatocellular carcinoma	69.5
Virologic failure	67.1
Erosive duodenitis	60.1

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Paritaprevir is on its molecule page.

• Molecular formula: C₄₀H₄₃N₇O₇S
• Molecular weight: 765.89 g/mol
• CAS number: 1216941-48-8
• InChIKey: UAUIUKWPKRJZJV-QPLHLKROSA-N
• PubChem CID: 45110509

CC1=NC=C(N=C1)C(=O)N[C@H]1CCCCC\C=C/[C@@H]2C[C@]2(NC(=O)[C@@H]2C[C@H](CN2C1=O)OC1=NC2=CC=CC=C2C2=CC=CC=C12)C(=O)NS(=O)(=O)C1CC1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Paritaprevir used for?

DrugCentral lists the following indications for Paritaprevir: Chronic hepatitis C.

How does Paritaprevir work?

Paritaprevir is classified as Breast Cancer Resistance Protein Inhibitors, HCV NS3/4A Protease Inhibitors and Organic Anion Transporting Polypeptide 1B1 Inhibitors.

When was Paritaprevir first approved?

Paritaprevir was first approved by the EMA in 2014.

What drug class does Paritaprevir belong to?

Paritaprevir is in the Hepatitis C Virus NS3/4A Protease Inhibitor class.

What is the chemical formula of Paritaprevir?

Paritaprevir has the molecular formula C40H43N7O7S and a molecular weight of 765.89 g/mol.

Sources

• DrugCentral drug card 4913 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL3391662 — compound record and bioactivity
• PubChem CID 45110509 — chemical identifiers
• DrugBank DB09297 — drug record
• FDA UNII OU2YM37K86 — substance identity
• DailyMed: FDA labels for Paritaprevir — current prescribing information (label search)
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.